Compare INDI & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INDI | SPRY |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 906.0M | 788.5M |
| IPO Year | 2021 | 2020 |
| Metric | INDI | SPRY |
|---|---|---|
| Price | $5.25 | $9.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $6.25 | ★ $40.00 |
| AVG Volume (30 Days) | ★ 5.7M | 1.7M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.95 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $217,394,000.00 | $84,278,000.00 |
| Revenue This Year | $25.54 | $87.40 |
| Revenue Next Year | $38.45 | $81.64 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.33 | N/A |
| 52 Week Low | $2.32 | $6.66 |
| 52 Week High | $6.05 | $18.63 |
| Indicator | INDI | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 70.74 | 64.81 |
| Support Level | $5.16 | $7.82 |
| Resistance Level | $6.01 | $9.51 |
| Average True Range (ATR) | 0.39 | 0.59 |
| MACD | 0.06 | 0.11 |
| Stochastic Oscillator | 86.74 | 92.22 |
Indie Semiconductor Inc caters to the autotech industry with semiconductors, photonics, and software platforms. The company's products include devices for a multitude of automotive applications spanning vision and radar processors, in-cabin wireless charging and USB power delivery, device interfacing through Apple CarPlay and Android Auto, and high-speed video and data connectivity. New products under evaluation or development include LiDAR, cybersecurity-enabled microcontrollers, and sensor-fusion processors. Its Photonics division mainly offers low-noise lasers, standard, and custom light sources. Geographically, the company generates the majority of its revenue from Greater China and the rest from the United States, Europe, South Korea, and other regions.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.